Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2606337 | 0.84 | SMN1; SMN2 (0.43) | SMN1; SMN2NPC1GAARAB9ACCNE1 | |
| SCHEMBL2665346 | 0.83 | CDK2 (0.37) | CCNE1CDK2CDK5 | |
| SCHEMBL9072537 | 0.83 | CDK2 (0.37) | CCNE1CDK2CDK5 | |
| SCHEMBL13639772 | 0.83 | CDK2 (0.37) | CCNE1CDK2CDK5 | |
| SCHEMBL2665362 | 0.81 | CDK2 (0.35) | SMN1; SMN2CCNE1CDK2CDK5 | |
| SCHEMBL2665341 | 0.81 | CDK2 (0.36) | CCNE1CDK2CDK5 | |
| SCHEMBL2665326 | 0.81 | CDK2 (0.36) | CCNE1CDK2CDK5 | |
| SCHEMBL2665339 | 0.81 | CDK2 (0.35) | SMN1; SMN2CCNE1CDK2CDK5 | |
| SCHEMBL2606408 | 0.81 | CDK2 (0.41) | CCNE1CDK2CDK5 | |
| SCHEMBL2606472 | 0.80 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1GAARAB9ACCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2444397-A1 | Heteroaryl-ureas and their use as glucokinase activators | Novo Nordisk A/S (DK) | 2012-04-25 | — | — | EP | disclosed |